PT  - JOURNAL ARTICLE
AU  - KAZUYUKI HAMADA
AU  - YUSUKE AOKI
AU  - JUN YAMAMOTO
AU  - CHIHIRO HOZUMI
AU  - MING ZHAO
AU  - TAKUYA MURATA
AU  - NORIHIKO SUGISAWA
AU  - MICHAEL BOUVET
AU  - TAKUYA TSUNODA
AU  - ROBERT M. HOFFMAN
TI  - <em>Salmonella typhimurium</em> A1-R Exquisitely Targets and Arrests a Matrix-producing Triple-negative Breast Carcinoma in a PDOX Model
AID  - 10.21873/invivo.12602
DP  - 2021 Nov 01
TA  - In Vivo
PG  - 3067--3071
VI  - 35
IP  - 6
4099  - http://iv.iiarjournals.org/content/35/6/3067.short
4100  - http://iv.iiarjournals.org/content/35/6/3067.full
SO  - In Vivo2021 Nov 01; 35
AB  - Background/Aim: Triple-negative matrix-producing breast carcinoma (MPBC) is rare, recalcitrant, and highly aggressive. The present study aimed to determine the efficacy of tumor-targeting leucine-arginine auxotroph Salmonella typhimurium (S. typhimurium) A1-R on a triple-negative MPBC in a patient-derived orthotopic xenograft (PDOX) model. Materials and Methods: The PDOX MPBC model was established in the left second mammary gland of nude mice by surgical orthotopic implantation (SOI). PDOX models were randomized into two groups when the tumor volume reached over 70 mm3: a control group (n=6); and a tumor-targeting S. typhimurium A1-R group (n=7), [intravenous (i.v.) injection of S. typhimurium A1-R via the tail vein, weekly, for two weeks]. All mice were sacrificed on day 14. Tumor volume and body weight were measured once per week. Results: S. typhimurium A1-R exquisitely targeted and arrested the growth of the MPBC PDOX compared to the control group (p=0.017). Conclusion: S. typhimurium A1-R has future clinical potential for triple-negative MPBC patients.